# Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

> **NCT00146770** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 45 (actual)

## Conditions studied

- Mucopolysaccharidosis I
- Hurler's Syndrome
- Hurler-Scheie Syndrome
- Scheie Syndrome

## Interventions

- **BIOLOGICAL:** Aldurazyme
- **BIOLOGICAL:** Aldurazyme
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00146770
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146770, "Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00146770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*